We have congregated information about stocks with the highest payout ratio as yet. The payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know and anything around 60 percent is considered high.
1. Terex Corporation
135.29% Payout Ratio
Terex Corporation manufactures and sells aerial work platforms, materials processing machinery, and cranes worldwide.
Terex Corporation's sales growth this year is expected to be negative 30% and 10.7% for next year.
Year-on-year quarterly revenue growth declined by 25.3%, now sitting on 3.17B for the twelve trailing months.
Terex Corporation's sales growth is negative 14.6% for the present quarter and negative 3.9% for the next. The company's growth estimates for the ongoing quarter and the next is negative 94.4% and 108.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.47%.
Terex Corporation's Stock Yearly Top and Bottom Value
Terex Corporation's stock is valued at $35.36 at 04:23 EST, under its 52-week high of $36.92 and way higher than its 52-week low of $11.54.
Terex Corporation's Moving Average
Terex Corporation's value is way higher than its 50-day moving average of $31.49 and way higher than its 200-day moving average of $23.19.2. Carlisle Companies Incorporated
33.09% Payout Ratio
Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products in the United States, Europe, Asia, Canada, Mexico, the Middle East, Africa, and internationally.
As maintained by Morningstar, Inc., the next dividend payment is on Nov 15, 2020, the estimated forward annual dividend rate is 2.1 and the estimated forward annual dividend yield is 1.35%.
Carlisle Companies Incorporated's sales growth this year is anticipated to be negative 11.6% and 5.6% for next year.
Year-on-year quarterly revenue growth declined by 12%, now sitting on 4.33B for the twelve trailing months.
Carlisle Companies Incorporated's sales growth is negative 6% for the current quarter and negative 0.9% for the next. The company's growth estimates for the present quarter is negative 35.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.32%.
Carlisle Companies Incorporated's Stock Yearly Top and Bottom Value
Carlisle Companies Incorporated's stock is valued at $156.60 at 04:23 EST, below its 52-week high of $169.86 and way higher than its 52-week low of $97.55.
Carlisle Companies Incorporated's Moving Average
Carlisle Companies Incorporated's value is above its 50-day moving average of $145.46 and way above its 200-day moving average of $129.04.3. Sempra Energy
63.21% Payout Ratio
Sempra Energy operates as an energy-services holding company in the United States and internationally.
According to Morningstar, Inc., the next dividend payment is on Dec 16, 2020, the estimated forward annual dividend rate is 4.18 and the estimated forward annual dividend yield is 3.2%.
Sempra Energy's sales growth this year is expected to be 4.6% and 4.2% for next year.
Year-on-year quarterly revenue growth declined by 4.1%, now sitting on 11.14B for the twelve trailing months.
Sempra Energy's sales growth is 13.7% for the ongoing ongoing quarter and 4.3% for the next. The company's growth estimates for the present quarter and the next is 14.2% and negative -14.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.92%.
Sempra Energy's Stock Yearly Top and Bottom Value
Sempra Energy's stock is valued at $130.70 at 04:23 EST, way under its 52-week high of $161.87 and way above its 52-week low of $88.00.
Sempra Energy's Moving Average
Sempra Energy's value is higher than its 50-day moving average of $130.40 and above its 200-day moving average of $125.50.4. AbbVie
99.35% Payout Ratio
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally.
According to Morningstar, Inc., the next dividend payment is on Jan 13, 2021, the estimated forward annual dividend rate is 5.2 and the estimated forward annual dividend yield is 5.03%.
AbbVie's sales growth this year is anticipated to be 37.2% and 17.9% for next year.
Year-on-year quarterly revenue growth grew by 52.2%, now sitting on 40.65B for the twelve trailing months.
AbbVie's sales growth is 57.7% for the ongoing current quarter and 50.4% for the next. The company's growth estimates for the present quarter and the next is 29.4% and 18.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 209.12%.
AbbVie's Stock Yearly Top and Bottom Value
AbbVie's stock is valued at $103.26 at 04:23 EST, under its 52-week high of $109.15 and way higher than its 52-week low of $62.55.
AbbVie's Moving Average
AbbVie's value is higher than its 50-day moving average of $102.12 and above its 200-day moving average of $94.85.Previous days news about AbbVie
Halozyme announces roche receives european commission approval for phesgo® (fixed-dose combination of perjeta® and herceptin® for subcutaneous injection) utilizing halozyme's enhanze® technology f.... According to Business Insider on Wed Dec 23, "Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. "
AbbVie: FDA approves imbruvica prescribing information update for waldenström's macroglobulinemia. According to Business Insider on Wed Dec 23, "AbbVie (ABBV) said Wednesday that the U.S. Food and Drug Administration or FDA approved the update of the IMBRUVICA (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström's macroglobulinemia (WM).", ""We're encouraged by this latest recognition from the FDA as it underscores our commitment to supporting those impacted by Waldenström's macroglobulinemia, a rare and incurable form of non-Hodgkin's lymphoma," said Danelle James, IMBRUVICA Global Development Lead of Pharmacyclics LLC, an AbbVie company."
5. Crescent Capital BDC, Inc.
117.88% Payout Ratio
Crescent Capital BDC, Inc. was incorporated in 2015 and is based in Los Angeles, California.
As stated by Morningstar, Inc., the next dividend payment is on Dec 29, 2020, the estimated forward annual dividend rate is 1.64 and the estimated forward annual dividend yield is 11.01%.
Crescent Capital BDC, Inc.'s sales growth this year is anticipated to be 43.2% and 12.9% for next year.
Year-on-year quarterly revenue growth grew by 25.9%, now sitting on 71.5M for the twelve trailing months.
Crescent Capital BDC, Inc.'s sales growth is 33.8% for the current present quarter and 7.7% for the next. The company's growth estimates for the next quarter is 6.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.4%.
Crescent Capital BDC, Inc.'s Stock Yearly Top and Bottom Value
Crescent Capital BDC, Inc.'s stock is valued at $14.98 at 04:23 EST, way below its 52-week high of $17.99 and way above its 52-week low of $6.21.